Special Issue

Breast Cancer Research: Charting Future Directions

Message from the Guest Editor

Breast cancer remains one of the most prevalent and complex malignancies affecting people worldwide, especially women. As our understanding of its molecular, genetic, and environmental underpinnings deepens, so does the need to rethink diagnosis. treatment, survivorship, and prevention strategies. This Special Issue titled "Breast Cancer Research: Charting" Future Directions" brings together cutting-edge studies, innovative methodologies, and forward-looking perspectives that aim to shape the next chapter in breast cancer research. It will highlight key advancements in personalized medicine, biomarkers for early detection, disparities in care, immunotherapy, and patient-reported outcomes. By fostering dialogue between clinicians and researchers, this Special Issue aims to not only reflect the current state of the field but also inspire new inquiries that will accelerate discovery and improve outcomes for all individuals affected by breast cancer. We hope it will serve as both a resource and a catalyst for researchers committed to advancing the science and management of breast cancer well into the future.

Guest Editor

Dr. Mohamad Adam Bujang

Clinical Research Centre, Sarawak General Hospital, Ministry of Health Malaysia, Kuching, Malaysia

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/242673

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).